Kolexia
Teixeira Luis
Médecine interne
Hôpital Saint-Louis
Paris, France
164 Activités
217 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Récidive tumorale locale Métastase tumorale Adénocarcinome Tumeurs du poumon Tumeurs du sein triple-négatives Carcinomes Tumeurs du pancréas COVID-19

Industries

Novartis
43 collaboration(s)
Dernière en 2023
Lilly
26 collaboration(s)
Dernière en 2023
AstraZeneca
17 collaboration(s)
Dernière en 2023
MSD
16 collaboration(s)
Dernière en 2023

Dernières activités

EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence
Essai Clinique (Lilly)   29 février 2024
REPARP: Prospective and Multicentric Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.
Essai Clinique (Artios Pharma Ltd)   26 février 2024
Access to oncology care in Mali: a qualitative study on breast cancer.
BMC cancer   15 janvier 2024
COVIDVAC OH: Multicenter, Observational Study of Anti-Sars-Cov2 Vaccine Efficacy in Patients With Malignant Pathologies Treated in the University Hospitals of AP-HP. Nord
Essai Clinique (Assistance publique – Hôpitaux de Paris)   30 décembre 2023
Etude ALEXANDRA : pas de place pour l’immunothérapie en adjuvant dans les tumeurs triple négatives localisées
Edimark   01 décembre 2023
ICRG0101: Multicenter Large-scale Validation Study of the Interest of Broadband Spectroscopy Analysis (Femto/Attosecond by Infrared Laser) on Liquid Biopsies in Breast Cancer Screening
Essai Clinique (Centre Jean-Perrin)   21 novembre 2023
SAFIR 03: A ctDNA Screening Program in Patients With HR+, HER2- Metastatic Breast Cancer for Detection of High-risk Relapse Patients on Any CDK4/6 Inhibitor and a Randomised Phase II Study Comparing Alpelisib Combined With Fulvestrant to Ribociclib Combined With Fulvestrant, in Patients With Persistent Targetable PIK3CA Mutations
Essai Clinique (Unicancer)   20 novembre 2023
Overall Survival With Circulating Tumor Cell Count-Driven Choice of Therapy in Advanced Breast Cancer: A Randomized Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   06 novembre 2023
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
Essai Clinique (Organisation européenne pour la recherche et le traitement du cancer)   02 novembre 2023
Impact of the COVID-19 pandemic on clinical presentation, treatments, and outcomes of new breast cancer patients: A retrospective multicenter cohort study.
Cancer medicine   01 novembre 2023